Literature DB >> 2645310

Characterization of material with epidermal growth factor immunoreactivity in human serum and platelets.

K Pesonen1, L Viinikka, G Myllylä, J Kiuru, J Perheentupa.   

Abstract

We investigated the molecular nature of the epidermal growth factor immunoreactivity (ir-EGF) in serum and platelets of normal subjects. In serum, ir-EGF appeared and increased during spontaneous blood coagulation, reaching a plateau in 2 h. The mean plateau measured by time-resolved immunofluorometric assay was 778 pg/mL [130 pmol/L; range, 465-1352 pg/mL (78-225 pmol/L)] for men (n = 66), and 774 pg/mL (129 pmoL/L; range, 521-1114 pg/mL (87-186 pmol/L)] for women (n = 33). Serum samples (n = 9), when examined under nonreducing conditions by high performance liquid chromatography, contained three mol wt components. Their approximate proportions averaged 56 +/- 6% (+/- SD) for a 140K component, 22 +/- 9% for a 67K component, and 22 +/- 6% for a component coeluting with the 6K EGF standard. The molecular size distribution of ir-EGF released from isolated platelets varied with the treatment of the platelets. After stimulation with a Ca2+ ionophore, the proportions of the 140K, 67K, and 6K components were 61 +/- 11%, 20 +/- 8%, and 17 +/- 4% (n = 5), respectively, as in serum. In addition, we found a small amount, (approximately 1%) of a 17K component. When platelets (n = 6) were ruptured by sonication and repeated freeze-thawing, the 67K component formed 53 +/- 7% of the total; the proportions of the 140K, 17K, and 6K components were 14 +/- 7%, 2.1 +/- 0.7%, and 31 +/- 4%, respectively. Under reducing conditions the 17K and 6K components remained intact, but part of the 140K component and all of the 67K component were cleaved to a 35-37K form. After protease digestion of the higher mol wt components, the ir-EGF was exclusively of the 6K form. The 67K and 6K components bound to the EGF receptor, whereas the 140K component bound inconsistently. We conclude that treatment of platelets with Ca2+ ionophore produces ir-EGF components similar to those found in incubated serum but different from those obtained by freeze-thawing. The 67K mol wt component appears to be the main storage form of EGF in platelets; at least two independent mechanisms appear to exist for EGF release.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2645310     DOI: 10.1210/jcem-68-2-486

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  5 in total

1.  Epidermal Growth Factor (EGF) Autocrine Activation of Human Platelets Promotes EGF Receptor-Dependent Oral Squamous Cell Carcinoma Invasion, Migration, and Epithelial Mesenchymal Transition.

Authors:  Rui Chen; Ge Jin; Wei Li; Thomas M McIntyre
Journal:  J Immunol       Date:  2018-08-27       Impact factor: 5.422

2.  Megakaryocyte synthesis is the source of epidermal growth factor in human platelets.

Authors:  J Ben-Ezra; K Sheibani; D L Hwang; A Lev-Ran
Journal:  Am J Pathol       Date:  1990-10       Impact factor: 4.307

3.  TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy.

Authors:  E Nievergall; J Reynolds; C H Kok; D B Watkins; M Biondo; S J Busfield; G Vairo; K Fuller; W N Erber; T Sadras; R Grose; D T Yeung; A F Lopez; D K Hiwase; T P Hughes; D L White
Journal:  Leukemia       Date:  2016-02-22       Impact factor: 11.528

4.  Factors affecting bovine corneal endothelial cell density in vitro.

Authors:  E W Johnstone; H C Wong; D J Coster; K A Williams
Journal:  Br J Ophthalmol       Date:  1996-03       Impact factor: 4.638

5.  The soluble protease ADAMDEC1 released from activated platelets hydrolyzes platelet membrane pro-epidermal growth factor (EGF) to active high-molecular-weight EGF.

Authors:  Rui Chen; Ge Jin; Thomas M McIntyre
Journal:  J Biol Chem       Date:  2017-04-28       Impact factor: 5.157

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.